Mission Pharmacal was founded in 1946 by the Walsdorf family, which still owns and runs the business. Mission Pharmacal Company makes prescription and over-the-counter (OTC) remedies for infection, kidney stones, and arthritis, and nutritional supplements. Mission's products include muscle ointment Thera-Gesic, Fosfree multivitamin supplement, kidney stone preventer Urocit-K, parasitic and bacterial infection fighter Tindamax, and CitraNatal prescription prenatal vitamins. The company also offers third-party OTC, nutritional, and prescription manufacturing, packaging, and inventory management from its Texas-based production facility.

NPS Pharmaceuticals, Inc. company was founded in 1986 and is headquartered in Bedminster, New Jersey. NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kyowa Kirin, and Nycomed.

Medarex is building the ultimate monoclonal antibody. Its UltiMAb technology utilizes transgenic mice whose antibody gene expression is suppressed to create fully human monoclonal antibodies (single-source proteins). Medarex has more than 40 antibodies for cancer, rheumatoid arthritis, and other autoimmune, inflammatory, and infectious diseases in clinical trials or pre-trial stages. The company has partnerships with numerous pharma and biotech firms including Genmab, which has licensed antibody therapies for leukemia, arthritis, and other conditions. Other development partners include Pfizer, Amgen, Eli Lilly, and Kirin. Another major collaborator, Bristol-Myers Squibb, acquired Medarex for $2.4 billion in 2009.

A. Nelson & Co. is Europe's oldest and the UK's largest manufacturer of homeopathic medicines and other natural healthcare products. Its homeopathic creams, ointments, sprays, and tablets treat a range of health problems from common colds to skin conditions. Its formulated remedies include Travella for travel sickness, Teetha for teething discomfort, Coldenza for cold and flu symptoms, Noctura for insomnia, and Pollenna for hay fever. The company is the manufacturer of Bach floral remedies, including the popular Rescue Remedy. Nelson distributes its products worldwide and operates specialized manufacturing labs in the UK. The company is owned by the Wilson family.

Allon Therapeutics Inc. company's primary focus is on developing treatments for Alzheimer's and other neurodegenerative diseases that lead to memory loss and cognitive impairment. Its lead candidate AL-108 is a nasal spray that has shown some efficacy in clinical trials in treating the symptoms of patients with amnestic mild cognitive impairment, a precursor to Alzheimer's. Allon has collaborations with the National Institute on Aging, the Alzheimer's Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University.

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. Its marketed products include SPECTRACEF for the treatment of mild to moderate infections, such as community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis and tonsillitis, and uncomplicated skin and skin-structure infections; ZYFLO CR for the prevention and chronic treatment of asthma in adults and children 12 years of age or older; and ALLERX Dose Pack products, which are oral tablets for the temporary relief of symptoms associated with allergic rhinitis.Cornerstone Therapeutics company also markets HYOMAX line of products, which consist of generic formulations of four antispasmodic medications containing the API hyoscyamine sulfate, an anticholinergic for functional intestinal disorders to reduce symptoms, such as those seen in mild dysenteries and diverticulitis; and BALACET 325, APAP 325, and APAP 500 for the relief of mild to moderate pain. In addition, its products under development include SPECTRACEF Once Daily for acute bacterial exacerbations of chronic bronchitis with COPD; SPECTRACEF Suspension for pharyngitis and tonsillitis, and acute otitis media; CRTX 058 for temporary relief of symptoms associated with allergic rhinitis; and CRTX 067 and CRTX 069 for temporary relief of symptoms associated with cough, and upper respiratory symptoms associated with allergies or a cold.

U.S. Genomics, Inc. company has developed the GeneEngine, a DNA sequencer that mimics natural cell division, rapidly reading and copying DNA. It is developing the technology to quickly detect and identify infectious pathogens and biomarkers for biodefense and diagnostic use. Its products can detect and quantify molecules of DNA, RNA, and proteins without amplification. Backed by private equity investors and biomedical firms including Becton Dickinson, U.S. Genomics has netted contracts with the Department of Homeland Security. Northrup Gruman is the company's bio-security development partner.

New Energy Technologies, Inc. was founded in 1998 and is based in Burtonsville, Maryland. New Energy Technologies, Inc., through its subsidiaries, engages in the identification, acquisition, development, and commercialization of alternative energy technologies. It focuses on the development of MotionPower, a technology for capturing the kinetic energy of moving vehicles in order to use this captured energy to generate electricity; and SolarWindow, a technology that enables transparent glass windows to generate electricity by coating their glass surfaces with small solar cells. The company was formerly known as Octillion Corp. and changed its name to New Energy Technologies, Inc. in January 2009.

Targeted Genetics is putting the bull's-eye on disease. The drug developer is working in the promising (though as yet unproven) field of gene therapies, drugs that deliver particular DNA sequences into targeted cells to encourage (or sometimes inhibit) the production of proteins associated with disease. The company's drug candidates -- targeting conditions such as retinal dystrophies, lateral sclerosis, HIV/AIDS, heart failure, and Huntington's disease -- employ proprietary technology using bio-engineered viral cells (called vectors) to deliver the genes. The company is working on its own to develop therapies for certain candidates and with development partners on some other programs.

Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.